Jason Cavalier
2021
In 2021, Jason Cavalier earned a total compensation of $782.9K as Chief Financial Officer at Lyra Therapeutics.
Compensation breakdown
| Non-Equity Incentive Plan | $51,200 |
|---|---|
| Option Awards | $605,892 |
| Salary | $123,077 |
| Other | $2,692 |
| Total | $782,861 |
Cavalier received $605.9K in option awards, accounting for 77% of the total pay in 2021.
Cavalier also received $51.2K in non-equity incentive plan, $123.1K in salary and $2.7K in other compensation.
Rankings
In 2021, Jason Cavalier's compensation ranked 9,547th out of 12,406 executives tracked by ExecPay. In other words, Cavalier earned more than 23.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 9,547 out of 12,406 | 23rd |
Division Manufacturing | 4,230 out of 5,494 | 23rd |
Major group Measuring, Analyzing, And Controlling Instruments; Photographic, Medical And Optical Goods; Watches And Clocks | 567 out of 798 | 29th |
Industry group Surgical, Medical, And Dental Instruments And Supplies | 364 out of 519 | 30th |
Industry Surgical and Medical Instruments and Apparatus | 228 out of 324 | 30th |
Source: SEC filing on April 27, 2022.
Cavalier's colleagues
We found three more compensation records of executives who worked with Jason Cavalier at Lyra Therapeutics in 2021.